{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:34:09Z","timestamp":1793205249705,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41440-022-00913-4","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T07:03:13Z","timestamp":1649919793000},"page":"967-975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Aldosterone breakthrough from a pharmacological perspective"],"prefix":"10.1038","volume":"45","author":[{"given":"Masaki","family":"Mogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"913_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res."},{"key":"913_CR2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323.","journal-title":"Am J Hypertens."},{"key":"913_CR3","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370\u20136.","journal-title":"Nat Med."},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41440-020-0468-3","volume":"43","author":"S Morimoto","year":"2020","unstructured":"Morimoto S, Ichihara A. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension. Hypertens Res. 2020;43:744\u201353.","journal-title":"Hypertens Res."},{"key":"913_CR5","first-page":"105","volume":"7","author":"EL Bravo","year":"1977","unstructured":"Bravo EL. Regulation of aldosterone secretion: current concepts and newer aspects. Adv Nephrol Necker Hosp. 1977;7:105\u201320.","journal-title":"Adv Nephrol Necker Hosp."},{"key":"913_CR6","doi-asserted-by":"publisher","first-page":"93S","DOI":"10.1093\/ajh\/3.6.93S","volume":"3","author":"C Missale","year":"1990","unstructured":"Missale C, Lombardi C, Sigala S, Spano PF. Dopaminergic regulation of aldosterone secretion. Biochemical mechanisms and pharmacology. Am J Hypertens. 1990;3:93S\u20135S.","journal-title":"Am J Hypertens."},{"key":"913_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1055\/a-1119-1063","volume":"52","author":"AG Lopez","year":"2020","unstructured":"Lopez AG, Duparc C, Naccache A, Castanet M, Lefebvre H, Louiset E. Role of mast cells in the control of aldosterone secretion. Horm Metab Res. 2020;52:412\u201320.","journal-title":"Horm Metab Res."},{"key":"913_CR8","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1161\/HYPERTENSIONAHA.117.09746","volume":"70","author":"HG Boyer","year":"2017","unstructured":"Boyer HG, Wils J, Renouf S, Arabo A, Duparc C, Boutelet I, et al. Dysregulation of aldosterone secretion in mast cell-deficient mice. Hypertension 2017;70:1256\u201363.","journal-title":"Hypertension"},{"key":"913_CR9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","volume":"132","author":"AC Huby","year":"2015","unstructured":"Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 2015;132:2134\u201345.","journal-title":"Circulation"},{"key":"913_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1210\/en.2011-1752","volume":"153","author":"Y Xing","year":"2012","unstructured":"Xing Y, Rainey WE, Apolzan JW, Francone OL, Harris RB, Bollag WB. Adrenal cell aldosterone production is stimulated by very-low-density lipoprotein (VLDL). Endocrinology 2012;153:721\u201331.","journal-title":"Endocrinology"},{"key":"913_CR11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1161\/01.HYP.15.6.744","volume":"15","author":"CE Gomez-Sanchez","year":"1990","unstructured":"Gomez-Sanchez CE, Cozza EN, Foecking MF, Chiou S, Ferris MW. Endothelin receptor subtypes and stimulation of aldosterone secretion. Hypertension 1990;15:744\u20137.","journal-title":"Hypertension"},{"key":"913_CR12","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/00005344-200111002-00013","volume":"38","author":"GP Rossi","year":"2001","unstructured":"Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC. The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol. 2001;38:S49\u201352.","journal-title":"J Cardiovasc Pharmacol."},{"key":"913_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1172\/JCI105561","volume":"46","author":"RD Gordon","year":"1967","unstructured":"Gordon RD, Kuchel O, Liddle GW, Island DP. Role of the sympathetic nervous system in regulating renin and aldosterone production in man. J Clin Investig. 1967;46:599\u2013605.","journal-title":"J Clin Investig."},{"key":"913_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16470-8","volume":"11","author":"J Wils","year":"2020","unstructured":"Wils J, Duparc C, Cailleux AF, Lopez AG, Guiheneuf C, Boutelet I, et al. The neuropeptide substance P regulates aldosterone secretion in human adrenals. Nat Commun. 2020;11:2673.","journal-title":"Nat Commun."},{"key":"913_CR15","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1210\/endo-124-3-1591","volume":"124","author":"TT Nguyen","year":"1989","unstructured":"Nguyen TT, Lazure C, Babinski K, Chretien M, Ong H, De Lean A. Aldosterone secretion inhibitory factor: a novel neuropeptide in bovine chromaffin cells. Endocrinology 1989;124:1591\u20133.","journal-title":"Endocrinology"},{"key":"913_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/endo.137.1.8536640","volume":"137","author":"M Kawai","year":"1996","unstructured":"Kawai M, Naruse M, Yoshimoto T, Naruse K, Shionoya K, Tanaka M, et al. C-type natriuretic peptide as a possible local modulator of aldosterone secretion in bovine adrenal zona glomerulosa. Endocrinology 1996;137:42\u20136.","journal-title":"Endocrinology"},{"key":"913_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/10641963.2014.987391","volume":"37","author":"S Miura","year":"2015","unstructured":"Miura S, Nakayama A, Tomita S, Matsuo Y, Suematsu Y, Saku K. Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide. Clin Exp Hypertens. 2015;37:353\u20137.","journal-title":"Clin Exp Hypertens."},{"key":"913_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/hr.2016.72","volume":"39","author":"SI Miura","year":"2016","unstructured":"Miura SI, Suematsu Y, Matsuo Y, Tomita S, Nakayama A, Goto M, et al. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line. Hypertens Res. 2016;39:758\u201363.","journal-title":"Hypertens Res."},{"key":"913_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1152\/physrev.00030.2003","volume":"84","author":"A Spat","year":"2004","unstructured":"Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84:489\u2013539.","journal-title":"Physiol Rev."},{"key":"913_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.RES.0000180753.63183.95","volume":"97","author":"LJ Min","year":"2005","unstructured":"Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res. 2005;97:434\u201342.","journal-title":"Circ Res."},{"key":"913_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cardiores.2007.07.008","volume":"76","author":"LJ Min","year":"2007","unstructured":"Min LJ, Mogi M, Iwanami J, Li JM, Sakata A, Fujita T, et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res. 2007;76:506\u201316.","journal-title":"Cardiovasc Res."},{"key":"913_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.arr.2008.12.002","volume":"8","author":"LJ Min","year":"2009","unstructured":"Min LJ, Mogi M, Iwai M, Horiuchi M. Signaling mechanisms of angiotensin II in regulating vascular senescence. Ageing Res Rev. 2009;8:113\u201321.","journal-title":"Ageing Res Rev."},{"key":"913_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","volume":"26","author":"J Suzuki","year":"2006","unstructured":"Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:917\u201321.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"913_CR24","first-page":"834","volume":"76","author":"Y Rautureau","year":"2011","unstructured":"Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids 2011;76:834\u20139.","journal-title":"Steroids"},{"key":"913_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1677\/joe.0.0910457","volume":"91","author":"J Staessen","year":"1981","unstructured":"Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457\u201365.","journal-title":"J Endocrinol."},{"key":"913_CR26","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.amjhyper.2007.09.001","volume":"20","author":"T Yoneda","year":"2007","unstructured":"Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, et al. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens. 2007;20:1329\u201333.","journal-title":"Am J Hypertens."},{"key":"913_CR27","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/hr.2013.74","volume":"36","author":"A Sato","year":"2013","unstructured":"Sato A, Fukuda S. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist. Hypertens Res. 2013;36:879\u201384.","journal-title":"Hypertens Res."},{"key":"913_CR28","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41440-020-0458-5","volume":"43","author":"A Hashimoto","year":"2020","unstructured":"Hashimoto A, Takeda Y, Karashima S, Kometani M, Aono D, Demura M, et al. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice. Hypertens Res. 2020;43:1099\u2013104.","journal-title":"Hypertens Res."},{"key":"913_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pr Nephrol. 2007;3:486\u201392.","journal-title":"Nat Clin Pr Nephrol."},{"key":"913_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrneph.2009.228","volume":"6","author":"RW Schrier","year":"2010","unstructured":"Schrier RW. Aldosterone \u2018escape\u2019 vs \u2018breakthrough\u2019. Nat Rev Nephrol. 2010;6:61.","journal-title":"Nat Rev Nephrol."},{"key":"913_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/147323000102900103","volume":"29","author":"A Sato","year":"2001","unstructured":"Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13\u201321.","journal-title":"J Int Med Res."},{"key":"913_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64\u20138.","journal-title":"Hypertension"},{"key":"913_CR33","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"KJ Schjoedt","year":"2004","unstructured":"Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004;47:1936\u20139.","journal-title":"Diabetologia"},{"key":"913_CR34","doi-asserted-by":"crossref","unstructured":"Koide M, Harraz OF, Dabertrand F, Longden TA, Ferris HR, Wellman GC, et al. Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease. J Clin Investig. 2021;131:e149029.","DOI":"10.1172\/JCI149029"},{"key":"913_CR35","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","volume":"16","author":"A Sato","year":"2003","unstructured":"Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003;16:781\u20138.","journal-title":"Am J Hypertens."},{"key":"913_CR36","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1210\/jc.2003-031746","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab. 2004;89:4493\u2013502.","journal-title":"J Clin Endocrinol Metab."},{"key":"913_CR37","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1210\/jcem.86.9.7859","volume":"86","author":"KD Wu","year":"2001","unstructured":"Wu KD, Chen YM, Chu TS, Chueh SC, Wu MH, Bor-Shen H. Expression and localization of human dopamine D2 and D4 receptor mRNA in the adrenal gland, aldosterone-producing adenoma, and pheochromocytoma. J Clin Endocrinol Metab. 2001;86:4460\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"913_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1677\/jme.0.0200183","volume":"20","author":"JG LeHoux","year":"1998","unstructured":"LeHoux JG, Lefebvre A. Transcriptional activity of the hamster CYP11B2 promoter in NCI-H295 cells stimulated by angiotensin II, potassium, forskolin and bisindolylmaleimide. J Mol Endocrinol. 1998;20:183\u201391.","journal-title":"J Mol Endocrinol."},{"key":"913_CR39","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1210\/jc.2006-2338","volume":"92","author":"HW Chang","year":"2007","unstructured":"Chang HW, Chu TS, Huang HY, Chueh SC, Wu VC, Chen YM, et al. Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab. 2007;92:1863\u201370.","journal-title":"J Clin Endocrinol Metab."},{"key":"913_CR40","doi-asserted-by":"publisher","first-page":"E622","DOI":"10.1152\/ajpendo.00657.2007","volume":"294","author":"HW Chang","year":"2008","unstructured":"Chang HW, Wu VC, Huang CY, Huang HY, Chen YM, Chu TS, et al. D4 dopamine receptor enhances angiotensin II-stimulated aldosterone secretion through PKC-epsilon and calcium signaling. Am J Physiol Endocrinol Metab. 2008;294:E622\u20139.","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"913_CR41","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","volume":"26","author":"S Perez-Lloret","year":"2017","unstructured":"Perez-Lloret S, Otero-Losada M, Toblli JE, Capani F. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson\u2019s disease. Expert Opin Investig Drugs. 2017;26:1163\u201373.","journal-title":"Expert Opin Investig Drugs."},{"key":"913_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/15734021113099990004","volume":"9","author":"K Ohshima","year":"2013","unstructured":"Ohshima K, Mogi M, Horiuchi M. Therapeutic approach for neuronal disease by regulating renin-angiotensin system. Curr Hypertens Rev. 2013;9:99\u2013107.","journal-title":"Curr Hypertens Rev."},{"key":"913_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1326-2-1","volume":"2","author":"TN Grammatopoulos","year":"2007","unstructured":"Grammatopoulos TN, Jones SM, Ahmadi FA, Hoover BR, Snell LD, Skoch J, et al. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener. 2007;2:1.","journal-title":"Mol Neurodegener."},{"key":"913_CR44","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/1470320315573680","volume":"16","author":"H Nakaoka","year":"2015","unstructured":"Nakaoka H, Mogi M, Kan-No H, Tsukuda K, Ohshima K, Wang XL, et al. Angiotensin II type 2 receptor signaling affects dopamine levels in the brain and prevents binge eating disorder. J Renin Angiotensin Aldosterone Syst. 2015;16:749\u201357.","journal-title":"J Renin Angiotensin Aldosterone Syst."},{"key":"913_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/01.HYP.0000022606.52221.2F","volume":"40","author":"M Naruse","year":"2002","unstructured":"Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002;40:28\u201333.","journal-title":"Hypertension"},{"key":"913_CR46","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1055\/s-2007-978918","volume":"30","author":"A Tanabe","year":"1998","unstructured":"Tanabe A, Naruse M, Arai K, Naruse K, Yoshimoto T, Seki T, et al. Gene expression and roles of angiotensin II type 1 and type 2 receptors in human adrenals. Horm Metab Res. 1998;30:490\u20135.","journal-title":"Horm Metab Res."},{"key":"913_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/07435809809031866","volume":"24","author":"G Mazzocchi","year":"1998","unstructured":"Mazzocchi G, Gottardo G, Macchi V, Malendowicz LK, Nussdorfer GG. The AT2 receptor-mediated stimulation of adrenal catecholamine release may potentiate the AT1 receptor-mediated aldosterone secretagogue action of angiotensin-II in rats. Endocr Res. 1998;24:17\u201328.","journal-title":"Endocr Res."},{"key":"913_CR48","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1210\/en.2010-1070","volume":"152","author":"J Yatabe","year":"2011","unstructured":"Yatabe J, Yoneda M, Yatabe MS, Watanabe T, Felder RA, Jose PA, et al. Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor. Endocrinology 2011;152:1582\u20138.","journal-title":"Endocrinology"},{"key":"913_CR49","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.3390\/ijms22094587","volume":"22","author":"Y Takeda","year":"2021","unstructured":"Takeda Y, Demura M, Yoneda T, Takeda Y. DNA Methylation of the angiotensinogen gene, AGT, and the aldosterone synthase gene, CYP11B2 in cardiovascular diseases. Int J Mol Sci. 2021;22:4587.","journal-title":"Int J Mol Sci."},{"key":"913_CR50","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1210\/en.2007-1476","volume":"149","author":"H Otani","year":"2008","unstructured":"Otani H, Otsuka F, Inagaki K, Suzuki J, Miyoshi T, Kano Y, et al. Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 2008;149:2816\u201325.","journal-title":"Endocrinology"},{"key":"913_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mce.2003.10.046","volume":"217","author":"A Spat","year":"2004","unstructured":"Spat A. Glomerulosa cell\u2013a unique sensor of extracellular K+ concentration. Mol Cell Endocrinol. 2004;217:23\u20136.","journal-title":"Mol Cell Endocrinol."},{"key":"913_CR52","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/j.1523-1755.2004.00626.x","volume":"65","author":"MN Kerstens","year":"2004","unstructured":"Kerstens MN, van der Kleij FG, Boonstra AH, Sluiter WJ, van der Molen JC, Navis G, et al. Angiotensin administration stimulates renal 11 beta-hydroxysteroid dehydrogenase activity in healthy men. Kidney Int. 2004;65:2065\u201370.","journal-title":"Kidney Int"},{"key":"913_CR53","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.3390\/ijms22094762","volume":"22","author":"M Adamcova","year":"2021","unstructured":"Adamcova M, Kawano I, Simko F. The impact of microRNAs in renin-angiotensin-system-induced cardiac remodelling. Int J Mol Sci. 2021;22:4762.","journal-title":"Int J Mol Sci."},{"key":"913_CR54","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1152\/physiolgenomics.00084.2014","volume":"46","author":"S Maharjan","year":"2014","unstructured":"Maharjan S, Mopidevi B, Kaw MK, Puri N, Kumar A. Human aldosterone synthase gene polymorphism promotes miRNA binding and regulates gene expression. Physiol Genom. 2014;46:860\u20135.","journal-title":"Physiol Genom."},{"key":"913_CR55","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/ejhf.1813","volume":"22","author":"A Garg","year":"2020","unstructured":"Garg A, Foinquinos A, Jung M, Janssen-Peters H, Biss S, Bauersachs J, et al. MiRNA-181a is a novel regulator of aldosterone-mineralocorticoid receptor-mediated cardiac remodelling. Eur J Heart Fail. 2020;22:1366\u201377.","journal-title":"Eur J Heart Fail."},{"key":"913_CR56","doi-asserted-by":"publisher","first-page":"C521","DOI":"10.1152\/ajpcell.00026.2015","volume":"308","author":"MB Butterworth","year":"2015","unstructured":"Butterworth MB. MicroRNAs and the regulation of aldosterone signaling in the kidney. Am J Physiol Cell Physiol. 2015;308:C521\u20137.","journal-title":"Am J Physiol Cell Physiol."},{"key":"913_CR57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"AS Bomback","year":"2008","unstructured":"Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51:199\u2013211.","journal-title":"Am J Kidney Dis."},{"key":"913_CR58","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/HYPERTENSIONAHA.121.18360","volume":"79","author":"T Oka","year":"2022","unstructured":"Oka T, Sakaguchi Y, Hattori K, Asahina Y, Kajimoto S, Doi Y, et al. Mineralocorticoid receptor antagonist use and hard renal outcomes in real-world patients with chronic kidney disease. Hypertension 2022;79:679\u201389.","journal-title":"Hypertension"},{"key":"913_CR59","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrd.2017.229","volume":"17","author":"JS Smith","year":"2018","unstructured":"Smith JS, Lefkowitz RJ, Rajagopal S. Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov. 2018;17:243\u201360.","journal-title":"Nat Rev Drug Discov."},{"key":"913_CR60","doi-asserted-by":"publisher","first-page":"109967","DOI":"10.1016\/j.cellsig.2021.109967","volume":"82","author":"KE Ferraino","year":"2021","unstructured":"Ferraino KE, Cora N, Pollard CM, Sizova A, Maning J, Lymperopoulos A. Adrenal angiotensin II type 1 receptor biased signaling: The case for \u201cbiased\u201d inverse agonism for effective aldosterone suppression. Cell Signal. 2021;82:109967.","journal-title":"Cell Signal."},{"key":"913_CR61","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1073\/pnas.0811706106","volume":"106","author":"A Lymperopoulos","year":"2009","unstructured":"Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ. An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci USA 2009;106:5825\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"913_CR62","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5761\/atcs.oa.16-00054","volume":"22","author":"A Sezai","year":"2016","unstructured":"Sezai A, Osaka S, Yaoita H, Arimoto M, Hata H, Shiono M, et al. Changeover trial of azilsartan and olmesartan comparing effects on the renin-angiotensin-aldosterone system in patients with essential hypertension after cardiac surgery (CHAOS Study). Ann Thorac Cardiovasc Surg. 2016;22:161\u20137.","journal-title":"Ann Thorac Cardiovasc Surg."},{"key":"913_CR63","doi-asserted-by":"publisher","first-page":"487","DOI":"10.5761\/atcs.oa.11.01691","volume":"17","author":"A Sezai","year":"2011","unstructured":"Sezai A, Soma M, Hata M, Yoshitake I, Unosawa S, Wakui S, et al. Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery\u2013investigation using a candesartan change-over study. Ann Thorac Cardiovasc Surg. 2011;17:487\u201393.","journal-title":"Ann Thorac Cardiovasc Surg."},{"key":"913_CR64","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/hr.2009.192","volume":"33","author":"T Tsutamoto","year":"2010","unstructured":"Tsutamoto T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, Yamamoto T, et al. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res. 2010;33:118\u201322.","journal-title":"Hypertens Res."},{"key":"913_CR65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2010.1949","volume":"305","author":"M Eklind-Cervenka","year":"2011","unstructured":"Eklind-Cervenka M, Benson L, Dahlstrom U, Edner M, Rosenqvist M, Lund LH. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011;305:175\u201382.","journal-title":"JAMA"},{"key":"913_CR66","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1001\/jama.2012.452","volume":"307","author":"H Svanstrom","year":"2012","unstructured":"Svanstrom H, Pasternak B, Hviid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA 2012;307:1506\u201312.","journal-title":"JAMA"},{"key":"913_CR67","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1074\/jbc.M117.813139","volume":"293","author":"AD Toth","year":"2018","unstructured":"Toth AD, Prokop S, Gyombolai P, Varnai P, Balla A, Gurevich VV, et al. Heterologous phosphorylation-induced formation of a stability lock permits regulation of inactive receptors by beta-arrestins. J Biol Chem. 2018;293:876\u201392.","journal-title":"J Biol Chem."},{"key":"913_CR68","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12272-021-01320-y","volume":"44","author":"N Sun","year":"2021","unstructured":"Sun N, Kim KM. Mechanistic diversity involved in the desensitization of G protein-coupled receptors. Arch Pharm Res. 2021;44:342\u201353.","journal-title":"Arch Pharm Res."},{"key":"913_CR69","doi-asserted-by":"publisher","first-page":"R1095","DOI":"10.1152\/ajpregu.2001.280.4.R1095","volume":"280","author":"E Moellenhoff","year":"2001","unstructured":"Moellenhoff E, Blume A, Culman J, Chatterjee B, Herdegen T, Lebrun CJ, et al. Effect of repetitive icv injections of ANG II on c-Fos and AT(1)-receptor expression in the rat brain. Am J Physiol Regul Integr Comp Physiol. 2001;280:R1095\u2013104.","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"913_CR70","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1113\/expphysiol.2012.065771","volume":"97","author":"PJ Vento","year":"2012","unstructured":"Vento PJ, Daniels D. Mitogen-activated protein kinase is required for the behavioural desensitization that occurs after repeated injections of angiotensin II. Exp Physiol. 2012;97:1305\u201314.","journal-title":"Exp Physiol"},{"key":"913_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/JME-10-0014","volume":"45","author":"D Calebiro","year":"2010","unstructured":"Calebiro D, Nikolaev VO, Lohse MJ. Imaging of persistent cAMP signaling by internalized G protein-coupled receptors. J Mol Endocrinol. 2010;45:1\u20138.","journal-title":"J Mol Endocrinol."},{"key":"913_CR72","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fcell.2019.00043","volume":"7","author":"JC Burton","year":"2019","unstructured":"Burton JC, Grimsey NJ. Ubiquitination as a key regulator of endosomal signaling by GPCRs. Front Cell Dev Biol. 2019;7:43.","journal-title":"Front Cell Dev Biol."},{"key":"913_CR73","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1016\/S0021-9258(19)86930-2","volume":"254","author":"K Fujita","year":"1979","unstructured":"Fujita K, Aguilera G, Catt KJ. The role of cyclic AMP in aldosterone production by isolated zona glomerulosa cells. J Biol Chem. 1979;254:8567\u201374.","journal-title":"J Biol Chem."},{"key":"913_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24968-y","volume":"12","author":"J Giubilaro","year":"2021","unstructured":"Giubilaro J, Schuetz DA, Stepniewski TM, Namkung Y, Khoury E, Lara-Marquez M, et al. Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen. Nat Commun. 2021;12:4688.","journal-title":"Nat Commun."},{"key":"913_CR75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1254\/jphs.09343SC","volume":"112","author":"MA Bhuiyan","year":"2010","unstructured":"Bhuiyan MA, Hossain M, Nakamura T, Ozaki M, Nagatomo T. Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan. J Pharm Sci. 2010;112:459\u201362.","journal-title":"J Pharm Sci."},{"key":"913_CR76","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","volume":"64","author":"MR Deshotels","year":"2014","unstructured":"Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension 2014;64:1368\u201375.","journal-title":"Hypertension"},{"key":"913_CR77","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3389\/fphar.2020.01179","volume":"11","author":"NL Rukavina Mikusic","year":"2020","unstructured":"Rukavina Mikusic NL, Silva MG, Pineda AM, Gironacci MM. Angiotensin receptors heterodimerization and trafficking: how much do they influence their biological function? Front Pharmacol. 2020;11:1179.","journal-title":"Front Pharmacol."},{"key":"913_CR78","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bcp.2015.05.006","volume":"96","author":"E Martinez-Pinilla","year":"2015","unstructured":"Martinez-Pinilla E, Rodriguez-Perez AI, Navarro G, Aguinaga D, Moreno E, Lanciego JL, et al. Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum. Biochem Pharmacol. 2015;96:131\u201342.","journal-title":"Biochem Pharmacol."},{"key":"913_CR79","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1172\/JCI33637C1","volume":"118","author":"H Li","year":"2008","unstructured":"Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, et al. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J Clin Investig. 2008;118:2180\u20139.","journal-title":"J Clin Investig."},{"key":"913_CR80","doi-asserted-by":"crossref","unstructured":"O\u2019Connor PJ, Sperl-Hillen JAM, Johnson PE, Rush WA, Biltz G. Clinical inertia and outpatient medical errors. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21249838.): Rockville (MD), 2005.","DOI":"10.1037\/e448252006-001"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00913-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00913-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00913-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T14:06:19Z","timestamp":1661522779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00913-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-00913-4","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}